C07D 487/12
In which the condensed system contains three hetero rings
Official title: in which the condensed system contains three hetero rings
C07D487/12 (In which the condensed system contains three hetero rings) appears on 1,816 US grants and 2,129 published applications in this corpus.
Search patents in C07D- Granted patents
- 1,816
- Published applications
- 2,129
- Assignees
- 884
- Inventors
- 5,872
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 8 | 0 |
| 1977 | 9 | 0 |
| 1978 | 15 | 0 |
| 1979 | 6 | 0 |
| 1980 | 10 | 0 |
| 1981 | 12 | 0 |
| 1982 | 27 | 0 |
| 1983 | 18 | 0 |
| 1984 | 13 | 0 |
| 1985 | 5 | 0 |
| 1986 | 13 | 0 |
| 1987 | 14 | 0 |
| 1988 | 16 | 0 |
| 1989 | 18 | 0 |
| 1990 | 10 | 0 |
| 1991 | 15 | 0 |
| 1992 | 19 | 0 |
| 1993 | 27 | 0 |
| 1994 | 12 | 0 |
| 1995 | 19 | 0 |
| 1996 | 21 | 0 |
| 1997 | 27 | 0 |
| 1998 | 18 | 0 |
| 1999 | 14 | 0 |
| 2000 | 10 | 0 |
| 2001 | 10 | 3 |
| 2002 | 18 | 16 |
| 2003 | 17 | 31 |
| 2004 | 10 | 35 |
| 2005 | 23 | 40 |
| 2006 | 29 | 45 |
| 2007 | 24 | 41 |
| 2008 | 26 | 34 |
| 2009 | 32 | 52 |
| 2010 | 24 | 53 |
| 2011 | 29 | 70 |
| 2012 | 45 | 81 |
| 2013 | 65 | 86 |
| 2014 | 75 | 123 |
| 2015 | 92 | 116 |
| 2016 | 106 | 128 |
| 2017 | 106 | 124 |
| 2018 | 103 | 97 |
| 2019 | 85 | 106 |
| 2020 | 66 | 106 |
| 2021 | 67 | 123 |
| 2022 | 79 | 134 |
| 2023 | 77 | 172 |
| 2024 | 91 | 120 |
| 2025 | 92 | 125 |
| 2026 | 49 | 68 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Materials for organic electroluminescent devices15 Sep 2026US 12,735,436 B2Universal Display Corporation
- Tricyclic derivatives and related uses1 Sep 2026US 12,723,045 B2MOMA Therapeutics, Inc.
- Compounds comprising a linker for increasing transcyclooctene stability25 Aug 2026US 12,714,752 B2Tagworks Pharmaceuticals B.V.
- Macrocyclic diamine derivatives as ENT inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists25 Aug 2026US 12,715,880 B2iTeos Belgium SA
- Composition material for organic electroluminescent device, plurality of host materials, and organic electroluminescent device comprising the same25 Aug 2026US 12,721,039 B2DuPont Specialty Materials Korea Ltd.
- Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof8 Oct 2026US 2026/0308162 A1
- Compositions, methods, and kits related to modulation of zinc transporter zip121 Oct 2026US 2026/0294887 A1West Virginia University Board of Governors on behalf of West Virginia University
- Compounds and methods of treating cancers1 Oct 2026US 2026/0297081 A1Cullgen Inc.
- Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof1 Oct 2026US 2026/0297101 A1
- Heterocyclic compounds as parp1 inhibitors1 Oct 2026US 2026/0297102 A1Synnovation Therapeutics, Inc.
Most cited
By later US patents
- 2,4-disubstituted pyrimidines useful as kinase inhibitors178US 8,338,439 B2Celgene Avilomics Research, Inc. · 2012
- 2,4-disubstituted pyrimidines useful as kinase inhibitors115US 8,450,335 B2Celgene Avilomics Research, Inc. · 2013
- Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders107US 7,622,451 B2University of Kansas · 2009
- Tetracyclic azepinoindole compounds100US 6,407,092 B1Pharmacia & Upjohn Company · 2002
- Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors97US 5,990,109 ABristol-Myers Squibb Company · 1999